Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine

CNS Drugs

Volumn 21, Issue 1, 2007, Pages 73-82

  Dodick, David W ^a   Sandrini, Giorgio ^b   Williams, Paul ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PAVIA   (Italy)

^c PAREXEL INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; HEADACHE; HUMAN; META ANALYSIS; MIGRAINE; PAIN ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 33846042038     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721010-00006     Document Type: Article

References (39)

1. Lipton RB, Stewart WF, Von Korff M. The burden of migraine: a review of cost to society. Pharmacoeconomics 1994; 6 (3): 215-21
2. Dahlöf CG, Solomon GD. The burden of migraine to the individual sufferer: a review. Eur J Neurol 1998; 5 (6): 525-33
3. Solomon GD, Skobieranda FG, Genzen JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995; 35: 449-54
4. Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther 1999; 21 (1): 190-204
5. Lofland JH, Johnson NE, Batenhorst AS, et al. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999; 159 (8): 857-63
6. Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58 (6): 885-94
7. Gibbs TS, Fleischer AB, Feldman SR, et al. Health care utilization in patients with migraine: demographics and patterns of care in the ambulatory setting. Headache 2003; 43 (4): 330-5
8. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62: 509-25
9. Goadsby PJ, Lipton RB, Ferrari MD. Migraine: current understanding and treatment. N Engl J Med 2002; 346 (4): 257-70
10. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999; 39 Suppl. 2: S20-6
11. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43 (1): 36-44
12. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004; 55 (1): 19-26
13. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache 1995; 35 (7): 387-96
14. Caro G, Caro JJ, O'Brien JA, et al. Migraine therapy: development and testing of a patient preference questionnaire. Headache 1998; 38 (8): 602-7
15. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002; 42 Suppl. 1: S3-9
16. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20 (6): 554-60
17. Santanello NC, Davies G, Allen C, et al. Determinants of migraine-specific quality of life. Cephalalgia 2002; 22 (8): 680-5
18. Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan odt 10-mg and sumatriptan 50-mg tablet in migraine. Headache 2001; 41 (8): 745-53
19. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991; 31 (5): 295-9
20. Tfelt-Hansen P, Block G, Dahl̈of C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000; 20 (9): 765-86
21. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: 633-58
22. Williams P, Reeder CE. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin Ther 2003; 25 (11): 2903-19
23. Williams P, Reeder CE. A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point. J Manag Care Pharm 2004; 10 (3): 259-65
24. Sandrini G, Dahlof CG, Mathew N, et al. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine. Int J Clin Pract 2005; 59 (11): 1356-65
25. US Geological Survey. Techniques of water resources investigations: book 4. Alternative methods for regression. In: Helsel DR, Hirsch RM, editors Statistical methods in water resources [online]. Available from URL: http://water.usgs.gov/pubs/twri/twri4a3/pdf/chapter10new.pdf [Accessed 2004 Aug 18]
26. Prins J, McCormack D, Michelson D, et al. What are outliers in the data? In: National Institute of Standards and Technology, Information Technology Laboratory. NIST/SEMATECH e-handbook of statistical methods [online]. Available from URL: http://www.itl.nist.gov/div898/handbook/prc/section1/prc16.htm [Accessed 2004 Aug 18]
27. Dodick D, Martin V. Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms. Cephalalgia 2004; 24 (6): 417-24
28. Pascual J, Munoz P. Correlation between lipophilicity and triptan outcomes. Headache 2005; 45 (1): 3-6
29. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation [online]. Available from URL: http://www.cebm.net/ levels_of_evidence.asp [Accessed 2004 May 1]
30. Nappi G, Sandrini G, Sances G. Tolerability of the triptans: clinical implications. Drug Saf 2003; 26 (2): 93-107
31. Sheftell FD, Feleppa M, Tepper SJ, et al. Assessment of adverse events associated with triptans - methods of assessment influence the results. Headache 2004; 44 (10): 978-82
32. Mathew N. A long-term open-label study of oral almotriptan 12.5mg for the treatment of acute migraine attacks. Headache 2002; 42: 32-40
33. Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001; 45 (4): 206-13
34. Spierings EL, Gomez-Mancilla B, Grosz DE, et al. Oral almotriptan vs oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001; 58 (6): 944-50
35. Dodick DW, Sandrini G. Relationship between sustained pain-free and adverse events: a comparison of almotriptan 12.5mg and other oral triptans in acute migraine. Headache 2004; 44: 468-9
36. Freedman DA. Ecological inference and the ecological fallacy [online]. Available from URL: http://stat-www.berkeley.edu/~census/549.pdf [Accessed 2004 May 1]
37. Mancini GB, Schulzer M. Reporting risks and benefits of therapy by use of the concepts of unqualified success and unmitigated failure: applications to highly cited trials in cardiovascular medicine. Circulation 1999; 99 (3): 377-83
38. Schulzer M, Mancini GB. 'Unqualified success' and 'unmitigated failure': number-needed-to-treat-related concepts for assessing treatment efficacy in the presence of treatment-induced adverse events. Int J Epidemiol 1996; 25 (4): 704-12
39. Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int J Clin Pract 2006; 60 (6): 698-706